Yahoo Finance

Certa Therapeutics Receives EU Orphan Designation for FT011, a GPR68 Inhibitor Being Developed as an Anti-Fibrotic Treatment for Systemic Sclerosis

MELBOURNE, Australia, July 22, 2024 (GLOBE NEWSWIRE) -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic ...
Yahoo Finance

Certa Therapeutics Expands GPR68 Platform through Acquisition of OccuRx

MELBOURNE, Australia, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with fibrotic diseases, today ...

Certa Named A Leader in the First Gartner(R) Magic Quadrant(TM) for Third-Party Risk Management Tools

This is the first time Gartner has published a Magic Quadrant for Third-Party Risk Management. To Certa, it signals that TPRM has moved from a back-office compliance exercise to a board-level ...
Business Wire

Certa and Castellum.AI Partner to Provide Compliance and Procurement Professionals with Enhanced Financial Crime Risk Data for Improved Third-Party Risk Management

SAN FRANCISCO--(BUSINESS WIRE)--Certa, the leader in third-party management solutions, today announced a partnership with Castellum.AI, a global financial crime risk platform. The partnership ...